Specifica, an IQVIA business的动态

Explore our extensively validated GPCR antibodies! ??? G protein-coupled receptors (GPCRs) are the largest superfamily of cell surface transmembrane receptors in the human genome, and they play a key role in the action of one-third of all prescribed drugs. Therefore, high-quality GPCR antibodies are crucial for academic, clinical and pharmaeutial research. ? Stringent Validation: GeneTex’s recombinant monoclonal GPCR antibodies are extensively validated for various applications including WB, IP, IHC, IFA, FACS, and ELISA. Their enhanced five-pillar validation ensures top-notch quality. GeneTex, Inc. – Setting the Standard for Antibody Quality With a 20-year history of quality results, GeneTex set themselves apart from other antibody companies by taking the necessary steps to properly validate their antibodies. ?? Large portfolio with over 54'000 primary and secondary antibodies ?? Five-pillar antibody validation program ?? Suitable for cancer, neuroscience, cell biology, and more Learn more about GeneTex: ?? https://lnkd.in/dX9jVt8d

A Glorious Beginning – Discovering Integrins and Early Therapeutic Success Part 2 of my integrin series. Integrin research began from three distinct areas that continue to shape our understanding: cancer biology, immunology, and blood coagulation. 1. Cancer Biology: Researchers found that transformed cancer cells had a reduced ability to remodel extracellular proteins like fibronectin, leading to the discovery of a fibronectin receptor. 2. Immunology: Patients with leukocyte adhesion deficiency lacked a crucial cell surface receptor necessary for their leukocytes to reach infection sites. 3. Blood Coagulation: Certain genetic bleeding disorders were traced to the absence of a specific cell surface receptor. Eventually, it became clear that these receptors were all part of the same family: integrins. In 1994, the FDA approved Abciximab, which targets the integrin αIIbβ3 to prevent blood clotting. This breakthrough has saved thousands from life-threatening thrombosis and sparked significant excitement in the field of integrin-targeted therapies. Unfortunately, this success story?eventually faced a somber halt. Stay tuned for the next part where we'll delve into the biggest disappointment in integrin-targeted pharmaceuticals. #Biopharma #Integrins #CancerResearch #Immunology #BloodCoagulation #DrugDevelopment #Pharmaceuticals #LifeSciences #Innovation #Biotech

Pleased to be able to share our latest paper / preprint. In our Nature Communications paper last year, we designed a machine-learning (ML) assisted pipeline for antibody property optimization and as a proof of concept discovered an antibody with a 50 picomolar Kd against the PD-L1 cancer target. In this paper, we redesign this pipeline to search for antibodies with high affinity to multiple targets and acceptable developability characteristics. As a proof of concept, we discover a highly human antibody with good predicted developability and low nanomolar to picomolar affinity to over 8 variants of the SARS-Cov2 spike protein RBD. We also introduce and evaluate several alternative uncertainty-aware ML algorithms for protein property prediction. https://lnkd.in/gR-t6EB7

Sharing a recent comprehensive article on the state of bispecifics and multispecific antibodies in oncology space ...for awareness Excerpt from the abstract: Research into bispecific antibodies, which are designed to simultaneously bind two antigens or epitopes, has advanced enormously over the past two decades. Owing to advances in protein engineering technologies and considerable preclinical research efforts, bispecific antibodies are constantly being developed and optimized to improve their efficacy and to mitigate toxicity. To date, >200 of these agents, the majority of which are bispecific immune cell engagers, are in either preclinical or clinical evaluation.

Looking for an overview of IgG structure and how effector function can be altered? A recent article published in Frontiers in Immunology provides an in-depth discussion about modifying IgG antibodies, including Fc region engineering and silencing. Read the article here: https://ow.ly/SbWN50QyO2W Discover Fc silencing services from Absolute Antibody: Fc Silent? Antibodies: https://ow.ly/iyNX50QyO2T mAbsolve STR Silencing: https://ow.ly/Q0RW50QyO2U

A recent publication of our esteemed group titled (Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction) has been published in Bioorganic Chemistry, where: ?? Novel pyrazolopyrimidines were designed as multitarget-directed drug candidates. ?? GI % against fifteen human cancer cell lines was recorded. ?? Cytotoxicity against HNO97, MDA-MB-468, FaDu, and HeLa were measured. ?? Compound 6l decreased EGFR protein concentration by a 6.10-fold change, compared to imatinib. ?? Compounds 6a and 6l exhibited IC50 values of 17.89 and 19.39 μM, respectively, against TOPO II. ?? DNA fragmentation images described the great potential of 6a and 6l in inducing DNA degradation. ?? Protein expression analysis for caspases 3, 7, 8, and 9, Bax, p53, MMP2, MMP9, and BCL-2 was conducted. ?? Cell cycle analysis and molecular docking were performed. Have an interesting reading with the nicely introduced rational design. Regards ?? #medicinalchemistry #rational #anticancer

Did you miss our June “In the Fold” newsletter? Every month, we keep you on the forefront of biologics discovery and development by sending you the latest innovations in R&D antibody/protein production right to your inbox. Here are the highlights of June’s newsletter: IGSF8: A New Cancer Target Revealed Through CRISPR Screens A new paper in Cell revealed that IGSF8 is overexpressed in tumors and suppresses NK cell cytotoxicity, linking to poor clinical outcomes. An anti-IGSF8 antibody boosted NK cell killing of malignant cells in vitro and inhibited tumor growth in vivo, alone or with anti-PD1. This study also found that tumors upregulate IGSF8 to mimic MHC-I expression and evade innate immunity, suggesting that targeting IGSF8 could be a promising cancer immunotherapy. Read the full article: https://shorturl.at/ywTfH Can Engineered Nanobodies Modulate GPCR Functions? A new study published in Nature Chemical Biology explored the potential of nanobodies as ligands for GPCRs. Using protein engineering, pharmacological assays, and structural studies, researchers developed nanobody antagonists that targeted the angiotensin II type I receptor. These nanobodies demonstrated unique receptor antagonism, altered receptor signaling, and modulated pharmacokinetic properties, highlighting their potential as novel therapeutics for complex GPCR modulation. Read the full article: https://shorturl.at/iZnao ?? Subscribe now: https://lnkd.in/eH4serWJ #researchnewsletter #scientificpaper #wuxibiologics #proteinengineering #pharmacological #nanobodies #pharmacokinetic #wuxibiologics

Congratulations Mariko Takahashi et al. for your latest paper published in Cell. Must read for anyone interested in covalent drug discovery and omics data to augment existing public databases, like us at Covant Therapeutics. Mariko and colleagues leverage the power of quantitative chemical proteomics to map cysteine reactivity and ligandability by small molecules across 416 cancer cell lines. Cysteine reactivity is impacted by a number of factors, including thiol/disulfide redox control, protein conformation (e.g. relative accessibility of the reactive residue), mutations, and post-translational modification states. As they demonstrate, any and all of these factors can vary across the heterogeneity of cellular lineages. Among the findings, the authors highlight the potential for covalent ligands to productively disrupt the activity of traditionally “difficult to drug” proteins, in this case oncogenic transcription factors. They exemplify the power and promise of this approach with NF-κB1 (blocking DNA binding), and SOX10 (increasing SOX10-SOX10 interactions and disrupting melanoma transcriptional signaling). #covalency #oncology #drugdiscovery #proteomics

By screening large numbers of naturally occurring TCells, these researchers found a TCell with a "Goldie Locks" phenotype, novel expression profile that's selective, cytotoxic and has a favorable safety profile. Once expanded and presented to the test subjects with various types of tumors, the TCells were also effective at killing many solid tumors with low toxicity and no long term neoplastic TCell transformation after over a year. It will be cool to see this in humans; excited to follow this new pharma. #oncologyresearch #immunooncology #singlecellanalysis #tcells

We are pleased to share the final program for 16th Annual Advancing Bispecifics and Combination Therapy to the Clinic at PEGS Europe at the Montjuic Palau de Congressos in Barcelona on 6 November 2024. View the final program and roster of speakers here https://lnkd.in/eEqtDsUb?? ?? Some of the biggest challenges in optimizing multispecific antibodies for clinical use are dose setting with two or more modalities, the activation and redirection of T cells to cancer cells and the accessibility and durability of targeting of solid tumors. Join experts in the field to examine practices and novel ideas for:?? ?? >Bispecific antibody IgA formats to block checkpoint inhibitors?? >Costimulatory bispecifics for solid tumors and hematologic malignancies?? >Improving success of bispecific antibodies in solid tumors ? ?? This year’s agenda will highlight successful strategies and approaches in preclinical and clinical development that are leading the way to more therapies entering the market. Join us for an engaging, interactive and rewarding event this 6 November in Barcelona. #PEGSEurope